Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Summary: The ability of mesenchymal stem cells (MSC) to suppress alloresponsiveness is poorly understood. Herein, an allogeneic mixed lymphocyte response was used as a model to investigate the mechanisms of MSC-mediated immunomodulation. Human MSC are demonstrated to express the immunosuppressive cytokines hepatocyte growth factor (HGF), interleukin (IL)-10 and transforming growth factor (TGF)-β1 at concentrations that suppress alloresponses in vitro. MSC also express cyclooxygenase 1 and 2 and produce prostaglandin E2 constitutively. Blocking studies with indomethacin confirmed that prostaglandins contribute to MSC-mediated allosuppression. The proinflammatory cytokine interferon (IFN)-γ did not ablate MSC inhibition of alloantigen-driven proliferation but up-regulated HGF and TGF-β1. IFN-γ also induced expression of indoleamine 2,3, dioxygenase (IDO), involved in tryptophan catabolism. Use of an antagonist, 1-methyl-L-tryptophan, restored alloresponsiveness and confirmed an IDO contribution to IFN-γ-induced immunomodulation by MSC. Addition of the tryptophan catabolite kynurenine to mixed lymphocyte reactions (MLR), blocked alloproliferation. These findings support a model where IDO exerts its effect through the local accumulation of tryptophan metabolites rather than through tryptophan depletion. Taken together, these data demonstrate that soluble factors, or products derived from MSC, modulate immune responses and suggest that MSC create an immunosuppressive microenvironment capable of modulating alloresponsiveness even in the presence of IFN-γ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00769-x · Cited by 2,295
Osteogenesis in transplants of bone marrow cells
Friedenstein, A. J., Piatetzky-Shapiro, I. I., & Petrakova, K. V. (1966) · Development · doi:10.1242/dev.16.3.381 · Cited by 1,671
Mesenchymal stem cells: clinical applications and biological characterization
Barry, F. P., & Murphy, J. M. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2003.11.001 · Cited by 1,665
Self-citationMeisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., & Ringdén, O. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00110-3 · Cited by 1,623
Cited by
Mesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746
Mesenchymal stem cell perspective: cell biology to clinical progress
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0083-6 · Cited by 2,008
Mechanisms involved in the therapeutic properties of mesenchymal stem cells
da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.10.002 · Cited by 1,436
“Low doses of IFN-g allow MSCs to express class II major histocompatibility complex (MHC) molecules and behave as antigen-presenting cells [78]; on the other hand, higher doses of IFN-g lead to a decrease in the surface levels of class II MHC molecules [78] and secretion of anti-inflammatory factors [79].”
BackgroundMesenchymal stem cells and immunomodulation: current status and future prospects
Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H.-L., Tse, H.-F., Fu, Q.-L., & Lian, Q. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.327 · Cited by 1,121
In Search of the In Vivo Identity of Mesenchymal Stem Cells
da Silva Meirelles, L., Caplan, A. I., & Nardi, N. B. (2008) · Stem Cells · doi:10.1634/stemcells.2007-1122 · Cited by 1,077
Mechanisms of mesenchymal stem/stromal cell function
Spees, J. L., Lee, R. H., & Gregory, C. A. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0363-7 · Cited by 891
Mesenchymal Stem Cells: Mechanisms of Inflammation
Singer, N. G., & Caplan, A. I. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130230 · Cited by 851
Zhang, Q., Shi, S., Liu, Y., Uyanne, J., Shi, Y., Shi, S., & Le, A. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902318 · Cited by 752
Mesenchymal Stem Cells: Mechanisms of Immunomodulation and Homing
Yagi, H., Soto-Gutierrez, A., Parekkadan, B., Kitagawa, Y., Tompkins, R. G., Kobayashi, N., & Yarmush, M. L. (2010) · Cell Transplantation · doi:10.3727/096368910x508762 · Cited by 701
François, M., Romieu-Mourez, R., Li, M., & Galipeau, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.189 · Cited by 694
English, K., Ryan, J. M., Tobin, L., Murphy, M. J., Barry, F. P., & Mahon, B. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03874.x · Cited by 676
Self-citationImmune modulation by mesenchymal stem cells
Jiang, W., & Xu, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12712 · Cited by 650
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Zhang, Q.-Z., Su, W.-R., Shi, S.-H., Wilder-Smith, P., Xiang, A. P., Wong, A., Nguyen, A. L., Kwon, C. W., & Le, A. D. (2010) · Stem Cells · doi:10.1002/stem.503 · Cited by 620
Madrigal, M., Rao, K. S., & Riordan, N. H. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0260-8 · Cited by 615
Species Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated Immunosuppression
Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., Zhang, J., Lu, Y., Roberts, A. I., Ji, W., et al. (2009) · Stem Cells · doi:10.1002/stem.118 · Cited by 597
Ghannam, S., Pène, J., Torcy-Moquet, G., Jorgensen, C., & Yssel, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902007 · Cited by 597
IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
Polchert, D., Sobinsky, J., Douglas, G., Kidd, M., Moadsiri, A., Reina, E., Genrich, K., Mehrotra, S., Setty, S., Smith, B., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200738129 · Cited by 581
Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning
Ferreira, J. R., Teixeira, G. Q., Santos, S. G., Barbosa, M. A., Almeida-Porada, G., & Gonçalves, R. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02837 · Cited by 572
Choudhery, M. S., Badowski, M., Muise, A., Pierce, J., & Harris, D. T. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-8 · Cited by 529
“Low immunoreactivity and high immunosuppressive properties make MSCs a suitable stem cell source for therapy [6,7].”
BackgroundMechanisms of mesenchymal stromal cell immunomodulation
English, K. (2013) · Immunology & Cell Biology · doi:10.1038/icb.2012.56 · Cited by 518
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications
Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C., & Noël, D. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt2 · Cited by 507
“This activation step has also been shown in vivo in a model of graft versus host disease (GVHD) since recipients of IFNγ -/T cells did not respond to MSC treatment and succumbed to GVHD [7].”
BackgroundPrasanna, S. J., Gopalakrishnan, D., Shankar, S. R., & Vasandan, A. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009016 · Cited by 467
Frenette, P. S., Pinho, S., Lucas, D., & Scheiermann, C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095919 · Cited by 462
MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation
Kean, T. J., Lin, P., Caplan, A. I., & Dennis, J. E. (2013) · Stem Cells International · doi:10.1155/2013/732742 · Cited by 433
Immunomodulatory properties of human periodontal ligament stem cells
Wada, N., Menicanin, D., Shi, S., Bartold, P. M., & Gronthos, S. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21710 · Cited by 426
Mahmoudi, M., Hosseinkhani, H., Hosseinkhani, M., Boutry, S., Simchi, A., Journeay, W. S., Subramani, K., & Laurent, S. (2011) · Chemical Reviews · doi:10.1021/cr1001832 · Cited by 418
Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413
Immunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications
Castro-Manrreza, M. E., & Montesinos, J. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/394917 · Cited by 399
Brennan, M. Á., Layrolle, P., & Mooney, D. J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909125 · Cited by 396
Immunomodulatory effects of mesenchymal stromal cells-derived exosome
Chen, W., Huang, Y., Han, J., Yu, L., Li, Y., Lu, Z., Li, H., Liu, Z., Shi, C., Duan, F., et al. (2016) · Immunologic Research · doi:10.1007/s12026-016-8798-6 · Cited by 343
Duijvestein, M., Wildenberg, M. E., Welling, M. M., Hennink, S., Molendijk, I., van Zuylen, V. L., Bosse, T., Vos, A. C. W., de Jonge-Muller, E. S. M., Roelofs, H., et al. (2011) · Stem Cells · doi:10.1002/stem.698 · Cited by 330
Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis
Riordan, N. H., Ichim, T. E., Min, W.-P., Wang, H., Solano, F., Lara, F., Alfaro, M., Rodriguez, J. P., Harman, R. J., Patel, A. N., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-29 · Cited by 324
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome
Xu, J., Wang, D., Liu, D., Fan, Z., Zhang, H., Liu, O., Ding, G., Gao, R., Zhang, C., Ding, Y., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391144 · Cited by 315
Costa, L. A., Eiro, N., Fraile, M., Gonzalez, L. O., Saá, J., Garcia-Portabella, P., Vega, B., Schneider, J., & Vizoso, F. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03600-0 · Cited by 313
Treatment of Inflammatory Diseases with Mesenchymal Stem Cells
Newman, R., Yoo, D., LeRoux, M., & Danilkovitch-Miagkova, A. (2009) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152809788462635 · Cited by 308
The Immunomodulatory Functions of Mesenchymal Stromal/Stem Cells Mediated via Paracrine Activity
Zhou, Y., Yamamoto, Y., Xiao, Z., & Ochiya, T. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071025 · Cited by 303
Mesenchymal Stromal Cells: Facilitators of Successful Transplantation?
English, K., French, A., & Wood, K. J. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.09.009 · Cited by 303
Opitz, C. A., Litzenburger, U. M., Lutz, C., Lanz, T. V., Tritschler, I., Köppel, A., Tolosa, E., Hoberg, M., Anderl, J., Aicher, W. K., et al. (2009) · Stem Cells · doi:10.1002/stem.7 · Cited by 299
Das, R., Jahr, H., van Osch, G. J. V. M., & Farrell, E. (2010) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2009.0296 · Cited by 297
Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells
Zangi, L., Margalit, R., Reich-Zeliger, S., Bachar-Lustig, E., Beilhack, A., Negrin, R., & Reisner, Y. (2009) · Stem Cells · doi:10.1002/stem.217 · Cited by 292
Immunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies
Griffin, M. D., Ritter, T., & Mahon, B. P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.156 · Cited by 289
Self-citationEnhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-γ
Kim, D. S., Jang, I. K., Lee, M. W., Ko, Y. J., Lee, D.-H., Lee, J. W., Sung, K. W., Koo, H. H., & Yoo, K. H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.002 · Cited by 287
Fekete, N., Gadelorge, M., Fürst, D., Maurer, C., Dausend, J., Fleury-Cappellesso, S., Mailänder, V., Lotfi, R., Ignatius, A., Sensebé, L., et al. (2012) · Cytotherapy · doi:10.3109/14653249.2012.655420 · Cited by 285
Immunomodulatory properties and therapeutic application of mesenchymal stem cells
Shi, M., Liu, Z.-W., & Wang, F.-S. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04327.x · Cited by 281
Najar, M., Raicevic, G., Boufker, H. I., Kazan, H. F., Bruyn, C. D., Meuleman, N., Bron, D., Toungouz, M., & Lagneaux, L. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.06.006 · Cited by 275
Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation
English, K., Barry, F. P., & Mahon, B. P. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.10.002 · Cited by 272
Self-citationDelaRosa, O., Lombardo, E., Beraza, A., Mancheño-Corvo, P., Ramirez, C., Menta, R., Rico, L., Camarillo, E., García, L., Abad, J. L., et al. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2008.0630 · Cited by 271
Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies
Iyer, S. S., & Rojas, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.5.569 · Cited by 269
Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266
Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252
Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?
Haddad, R., & Saldanha-Araujo, F. (2014) · BioMed Research International · doi:10.1155/2014/216806 · Cited by 188
Unraveling the Mesenchymal Stromal Cells' Paracrine Immunomodulatory Effects
Fontaine, M. J., Shih, H., Schäfer, R., & Pittenger, M. F. (2016) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2015.11.004 · Cited by 162
Li, M., Jiang, Y., Hou, Q., Zhao, Y., Zhong, L., & Fu, X. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02822-2 · Cited by 119
Gharibi, T., Ahmadi, M., Seyfizadeh, N., Jadidi-Niaragh, F., & Yousefi, M. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.01.002 · Cited by 104
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
Li, X., Xu, Z., Bai, J., Yang, S., Zhao, S., Zhang, Y., Chen, X., & Wang, Y. (2016) · Stem Cells International · doi:10.1155/2016/7495135 · Cited by 58
Scaffold-Mediated Immunoengineering as Innovative Strategy for Tendon Regeneration
Russo, V., El Khatib, M., Prencipe, G., Cerveró-Varona, A., Citeroni, M. R., Mauro, A., Berardinelli, P., Faydaver, M., Haidar-Montes, A. A., Turriani, M., et al. (2022) · Cells · doi:10.3390/cells11020266 · Cited by 49
Srinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.11.009 · Cited by 44
Castro-Manrreza, M. E., Bonifaz, L., Castro-Escamilla, O., Monroy-García, A., Cortés-Morales, A., Hernández-Estévez, E., Hernández-Cristino, J., Mayani, H., & Montesinos, J. J. (2019) · Stem Cells International · doi:10.1155/2019/4541797 · Cited by 24
Bobyleva, P. I., Andreeva, E. R., Gornostaeva, A. N., & Buravkova, L. B. (2016) · Stem Cells International · doi:10.1155/2016/4726267 · Cited by 21
Metadata
- Authors
- Ryan, J. M., Barry, F., Murphy, J. M., & Mahon, B. P.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-05-22
- Volume
- 149
- Issue
- 2
- Pages
- 353-363
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W2039751388
- Cited by
- 596
- References
- 49
- FWCI
- 13.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.